India’s Union health ministry has revoked the over-the-counter status of all medicinal syrups, including cough formulations, in a regulatory overhaul that took effect on Tuesday. The amendment to the Drugs Rules, 1945, removes syrups from Schedule K, a list of drugs previously exempt from prescription requirements and permitted for sale even in villages with fewer than 1,000 residents without a licensed pharmacy. From now on, consumers must present a valid doctor’s prescription to purchase any syrup-based medicine, and distribution in rural areas will be allowed only through licensed retail outlets compliant with the Drugs and Cosmetics Act, 1940. The move follows a series of tragic incidents in Madhya Pradesh and Rajasthan, where contaminated cough syrups were linked to the deaths of more than 20 children, prompting the World Health Organization to express “deep concerns” over India’s drug safety oversight.

Viewed from New Delhi, the amendment closes a long-standing regulatory gap that had left syrups loosely controlled alongside lozenges and certain tablets. The health ministry reviewed public feedback on draft proposals circulated in December before finalising the change. Indian doctors have broadly welcomed the decision, arguing that unrestricted access to cough syrups encouraged misuse, incorrect dosing, masking of underlying illnesses, dangerous drug interactions, and accidental poisoning among adolescents. The new requirement, they say, could significantly reduce such risks and compel more rigorous clinical assessment before these medicines are dispensed.

The Indian action unfolds amid wider regional anxieties over pharmaceutical supply chains. In Tehran, Health Minister Mohammadreza Zafarghandi recently warned that maritime disruptions linked to regional conflict had halted sea-borne imports of drug ingredients for nearly three months, forcing a shift to rail and air corridors. Iran, like India, depends heavily on China and India itself for raw materials, underscoring the interconnected vulnerabilities of medicine production across Asia. Viewed from Tehran, India’s regulatory tightening is a logical step to restore public confidence, but it also highlights how geopolitical shocks can strain the availability of essential drugs, making domestic quality control all the more urgent.

Analysts in London suggest that India’s prescription-only mandate for syrups may influence regulatory debates in other developing nations grappling with substandard and falsified medicines. The World Health Organization has repeatedly called for stronger post-market surveillance, and India’s move signals a willingness to align with those expectations. Yet enforcement remains the critical unknown: ensuring that every village pharmacy complies with licensing rules and that prescriptions are genuinely verified will test the capacity of state-level drug controllers. The reform is a necessary tightening, but its success will ultimately be measured not by the notification in the gazette, but by whether it prevents the next tragedy.